Fulgent Genetics raises FY23 EPS view to (95c) from ($1.25), consensus ($1.23)

Raises FY23 revenue view to $260M from $250M, consensus $255.94M. Paul Kim, CFO, added, “We are again raising our core guidance for the year due to our outperformance in the second quarter. Looking ahead, we believe our gross margins and operating margins will continue to improve as we implement efficiencies through our integration efforts. Our current cash position enables us to continue investing in our business.”